Wealth Enhancement Advisory Services, LLC Catalyst Pharmaceuticals, Inc. Transaction History
Wealth Enhancement Advisory Services, LLC
- $55.6 Billion
- Q2 2025
A detailed history of Wealth Enhancement Advisory Services, LLC transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Wealth Enhancement Advisory Services, LLC holds 31,755 shares of CPRX stock, worth $681,144. This represents 0.0% of its overall portfolio holdings.
Number of Shares
31,755
Previous 35,334
10.13%
Holding current value
$681,144
Previous $856,000
19.51%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding CPRX
# of Institutions
385Shares Held
99.7MCall Options Held
37KPut Options Held
20.5K-
Black Rock Inc. New York, NY18.7MShares$401 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.5MShares$182 Million0.0% of portfolio
-
State Street Corp Boston, MA5.53MShares$119 Million0.01% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.42MShares$73.4 Million2.1% of portfolio
-
Goldman Sachs Group Inc New York, NY3.14MShares$67.3 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.21B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...